Senetek Q2
This article was originally published in The Rose Sheet
Executive Summary
Higher sales of Revlon's Almay Kinetin skin care line and The Body Shop's Skin Re-Leaf with Kinetin product line contribute to 35.8% increase to $3.3 mil. in Senetek's second quarter sales, Kinetin manufacturer says. Senetek revenues also benefited from recognition of $230,000 in royalty income from one of its licensees and $870,000 in non-refundable deferred licensing fee as the result of termination and settlement of a licensing agreement with one of its licensees, Napa, Calif. firm adds. Net income for the quarter was $1.17 mil. compared to net loss of $505,000 the prior year...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.